These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9113005)

  • 1. End of the line for "third-generation-pill" controversy?
    Vandenbroucke JP; Rosendaal FR
    Lancet; 1997 Apr; 349(9059):1113-4. PubMed ID: 9113005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oral contraceptives on hemostasis and thrombosis.
    Rosing J; Tans G
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.
    Rintelen C; Mannhalter C; Ireland H; Lane DA; Knöbl P; Lechner K; Pabinger I
    Br J Haematol; 1996 May; 93(2):487-90. PubMed ID: 8639453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor V Leiden: should we screen oral contraceptive users and pregnant women?
    Vandenbroucke JP; van der Meer FJ; Helmerhorst FM; Rosendaal FR
    BMJ; 1996 Nov; 313(7065):1127-30. PubMed ID: 8916702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral contraceptive use before and after the latest pill scare in The Netherlands. Changes in oral contraceptive use and how users change.
    de Vries CS; van den Berg PB; de Jong-van den Berg LT
    Contraception; 1998 Apr; 57(4):247-9. PubMed ID: 9649916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation.
    Vandenbroucke JP; Helmerhorst FM; Bloemenkamp KW; Rosendaal FR
    Am J Obstet Gynecol; 1997 Oct; 177(4):887-91. PubMed ID: 9369840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.
    Martinelli I; Sacchi E; Landi G; Taioli E; Duca F; Mannucci PM
    N Engl J Med; 1998 Jun; 338(25):1793-7. PubMed ID: 9632445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral contraception and factor V Leiden mutation in relation to localization of deep vein thrombosis.
    Andersen BS; Olsen J
    Thromb Res; 1998 May; 90(4):191-4. PubMed ID: 9692618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 1995 pill scare revisited: anatomy of a non-epidemic.
    Spitzer WO
    Hum Reprod; 1997 Nov; 12(11):2347-57. PubMed ID: 9436662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
    Bennet L; Odeberg H
    J Intern Med; 1998 Jul; 244(1):27-32. PubMed ID: 9698021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
    Price DT; Ridker PM
    Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-generation oral contraceptives: how risky?
    Weiss N
    Lancet; 1995 Dec; 346(8990):1570. PubMed ID: 7500743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to activated protein C in healthy women taking oral contraceptives.
    Olivieri O; Friso S; Manzato F; Guella A; Bernardi F; Lunghi B; Girelli D; Azzini M; Brocco G; Russo C
    Br J Haematol; 1995 Oct; 91(2):465-70. PubMed ID: 8547095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro-progestins.
    Olivieri O; Friso S; Manzato F; Grazioli S; Bernardi F; Lunghi B; Girelli D; Azzini M; Brocco G; Russo C; Corrocher R
    Contraception; 1996 Sep; 54(3):149-52. PubMed ID: 8899255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptives and thrombotic disease: risk of venous thromboembolism.
    Helmerhorst FM; Bloemenkamp KW; Rosendaal FR; Vandenbroucke JP
    Thromb Haemost; 1997 Jul; 78(1):327-33. PubMed ID: 9198174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
    Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
    Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coagulation studies in women using combination type of oral contraceptives.
    Sharma S; Sharma M; Soni IJ; Gupta A; Jain R
    J Obstet Gynaecol India; 1983 Aug; 33(4):519-24. PubMed ID: 12339832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral contraceptives, venous thrombosis, and varicose veins. Royal College of General Practitioners' Oral Contraception Study.
    J R Coll Gen Pract; 1978 Jul; 28(192):393-9. PubMed ID: 702453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.